Grabar Law Office is investigating claims against Erasca, Insulet, Power Solutions International, and PROCEPT BioRobotics for alleged breaches of fiduciary duties and misleading shareholders. The investigations focus on issues such as misleading statements about drug development and clinical data at Erasca, manufacturing defects and safety risks at Insulet, overstated sales prospects at Power Solutions, and inflated sales figures due to discount programs at PROCEPT. Shareholders who held shares before specified dates are encouraged to seek corporate reforms and damages at no cost. These investigations could lead to significant legal and financial consequences for the companies involved.
Evotec reported a nearly 20% decline in revenue for the first half of 2026, alongside a sharp drop into negative adjusted EBITDA, signaling worsening fundamentals. Confidence in management's future targets has diminished, leading to a valuation based...
Shibarium has fixed its reported blockchain reorganization (reorg) issue as of September 19, 2026, resolving a key network disruption. However, the decentralized RPC (dRPC) migration and other infrastructure upgrades remain incomplete, with no set de...
Neutrl has opened redemptions for its NUSD stablecoin as the on-chain exchange rate approaches $0.51. This move allows holders to redeem their tokens, potentially stabilizing liquidity and market confidence. The redemption availability is significant...
US spot Bitcoin ETFs experienced significant inflows and outflows over five trading days, starting with $159.9 million inflows on Sept. 14, followed by $746.3 million in withdrawals over the next two days. However, demand returned strongly with $592....
X has filed a lawsuit in England against two named individuals and unidentified operators, accusing them of manipulating engagement across Bitcoin-focused accounts to fraudulently earn at least £207,384 through its Creator Revenue Sharing program. Th...
